Solid Cancer Clinical Trials

12 recruiting

Solid Cancer Trials at a Glance

37 actively recruiting trials for solid cancer are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 1 with 17 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Shanghai. Lead sponsors running solid cancer studies include Akeso, Hospices Civils de Lyon, and Institut Claudius Regaud.

Browse solid cancer trials by phase

Treatments under study

About Solid Cancer Clinical Trials

Looking for clinical trials for Solid Cancer? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 2

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting
Phase 1Phase 2

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Advanced Solid Cancers
BioNTech SE245 enrolled8 locationsNCT07186842
Recruiting
Phase 2Phase 3

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Advanced Solid Cancers
Intra-IMMUSG Pte Ltd52 enrolled4 locationsNCT07290088
Recruiting
Phase 1

An Antibody-armored Dendritic Cell in Patients With Solid Tumors

Adjuvant TherapySolid Cancers
Shanghai Cell Therapy Group Co.,Ltd8 enrolled1 locationNCT07479667
Recruiting
Early Phase 1

Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers

Advanced Solid Cancers
Hainan Cancer Hospital10 enrolled1 locationNCT07475182
Recruiting
Not Applicable

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

Solid Cancers
Institut Claudius Regaud770 enrolled3 locationsNCT03514368
Recruiting
Phase 1Phase 2

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Advanced Solid CancerKRAS G12D Mutation
Arvinas Inc.159 enrolled14 locationsNCT07023731
Recruiting
Phase 1

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Breast CancerColorectal, CancerOvarian Cancer+4 more
National Cancer Institute (NCI)210 enrolled1 locationNCT06253520
Recruiting
Phase 1

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

Metastatic Solid TumorsAdvanced Solid CancersAdvanced Malignancy
Adcytherix SAS290 enrolled4 locationsNCT07238075
Recruiting
Early Phase 1

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

Solid CancerGPC3 Positive Hepatocellular Carcinoma
Beijing GoBroad Hospital30 enrolled2 locationsNCT07242417
Recruiting
Phase 1Phase 2

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Endometrial CancerGastric (Stomach) CancerNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Beijing Tide Pharmaceutical Co., Ltd266 enrolled3 locationsNCT07371663
Recruiting
Phase 2Phase 3

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Solid Cancer
Daiichi Sankyo860 enrolled120 locationsNCT06161025
Recruiting
Phase 2

Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors

Solid CancerLymphopenia
Second Affiliated Hospital of Soochow University127 enrolled1 locationNCT07258160
Recruiting
Not Applicable

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Solid Cancer
Goethe University45 enrolled1 locationNCT07161310
Recruiting
Not Applicable

xDRIVE for Florida-based Cancer Patients

CancerLeukaemiaLymphoma+5 more
First Ascent Biomedical Inc.210 enrolled2 locationsNCT07167381
Recruiting
Phase 1

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.232 enrolled6 locationsNCT07265921
Recruiting
Phase 1

A Study of AK138D1 in Advanced Malignant Tumors

Solid Cancer
Akeso200 enrolled1 locationNCT07281326
Recruiting
Phase 2

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Drug ResistanceMetastatic Solid CancersRadiotherapy+3 more
Chuangzhen Chen48 enrolled1 locationNCT07071103
Recruiting
Phase 1

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid CancerAdvanced Solid Tumor (Phase 1)
Aptabio Therapeutics, Inc.110 enrolled3 locationsNCT07123415
Recruiting
Phase 1Phase 2

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

Advanced Solid Cancer
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT06985355